In conclusion, with a large collection of approximately 10,000 patients with breast cancer in Taiwan, this population-based cohort study showed that those taking non-COX-2 inhibitors and those receiving multiple NSAIDs during follow-up had a lower second cancer incidence in a dose-dependent manner. This evidence concerns the gene PTGS2 and breast carcinoma.